Merck Explores USD 28-32 Billion Buyout of Oncology Biotech Revolution Medicines
Merck & Co. is in discussions to acquire U.S.-based oncology biotech Revolution Medicines in a deal that could value the company between USD 28 billion and USD 32 billion, according to people familiar with the matter.
Merck Buyout Biotech Revolution Medicines | 11/01/2026 | By Darshana | 307
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy